FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

Clinical Study on the Efficacy and Safety of FOLFOX/FOLFIRI± Targeted Drug Regimen Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer

Inclusion Criteria:

• Male or female, ≥18 years old;
• Patients with histopathologically confirmed unresectable or metastatic colorectal cancer who have not previously received chemotherapy or targeted therapy for unresectable or metastatic lesions;
• Have at least one measurable lesion according to RECIST 1.1 standards;
• ECOG PS score: 0-2;
• Expected survival greater than 3 months;
• Routine blood routine, liver and kidney function, electrocardiogram and other routine tests were basically normal, no contraindications of chemotherapy;
• The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up visits;
• Researchers believe treatment can benefit.

Exclusion Criteria:

• A proven allergy to the test drug and/or its excipients;
• Pregnant or lactating women;
• Patients judged by the investigator to be unsuitable for inclusion in this study;